

# The Dopamine Transporter Recycles via a Retromer-Dependent Postendocytic Mechanism: Tracking Studies Using a Novel Fluorophore-Coupling Approach

Sijia Wu,<sup>1</sup>  Rita R. Fagan,<sup>1</sup> Chayasith Uttamapinant,<sup>2</sup>  Lawrence M. Lifshitz,<sup>3</sup> Kevin E. Fogarty,<sup>3</sup> Alice Y. Ting,<sup>4</sup> and  Haley E. Melikian<sup>1</sup>

<sup>1</sup>Brudnick Neuropsychiatric Research Institute, University of Massachusetts Medical School, Worcester, Massachusetts 01604, <sup>2</sup>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, <sup>3</sup>Biomedical Imaging Group, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, and <sup>4</sup>Departments of Genetics, Biology, and Chemistry, Stanford University, Stanford, California 94305

Presynaptic reuptake, mediated by the dopamine (DA) transporter (DAT), terminates DAergic neurotransmission and constrains extracellular DA levels. Addictive and therapeutic psychostimulants inhibit DA reuptake and multiple DAT coding variants have been reported in patients with neuropsychiatric disorders. These findings underscore that DAT is critical for DA neurotransmission and homeostasis. DAT surface availability is regulated acutely by endocytic trafficking, and considerable effort has been directed toward understanding mechanisms that govern DAT's plasma membrane expression and postendocytic fate. Multiple studies have demonstrated DAT endocytic recycling and enhanced surface delivery in response to various stimuli. Paradoxically, imaging studies have not detected DAT targeting to classic recycling endosomes, suggesting that internalized DAT targets to either degradation or an undefined recycling compartment. Here, we leveraged PRIME (PRobe Incorporation Mediated by Enzyme) labeling to couple surface DAT directly to fluorophore, and tracked DAT's postendocytic itinerary in immortalized mesencephalic cells. Following internalization, DAT robustly targeted to retromer-positive endosomes, and DAT/retromer colocalization was observed in male mouse dopaminergic somatodendritic and terminal regions. Short hairpin RNA-mediated Vps35 knockdown revealed that DAT endocytic recycling requires intact retromer. DAT also targeted rab7-positive endosomes with slow, linear kinetics that were unaffected by either accelerating DAT internalization or binding a high-affinity cocaine analog. However, cocaine increased DAT exit from retromer-positive endosomes significantly. Finally, we found that the DAT carboxy-terminal PDZ-binding motif was required for DAT recycling and exit from retromer. These results define the DAT recycling mechanism and provide a unifying explanation for previous, seemingly disparate, DAT endocytic trafficking findings.

**Key words:** cocaine; dopamine; endocytosis; retromer; reuptake; trafficking

## Significance Statement

The neuronal dopamine (DA) transporter (DAT) recaptures released DA and modulates DAergic neurotransmission, and a number of DAT coding variants have been reported in several DA-related disorders, including infantile parkinsonism, attention-deficit/hyperactivity disorder and autism spectrum disorder. DAT is also competitively inhibited by psychostimulants with high abuse potential. Therefore, mechanisms that acutely affect DAT availability will likely exert significant impact on both normal and pathological DAergic homeostasis. Here, we explore the cellular mechanisms that acutely control DAT surface expression. Our results reveal the intracellular mechanisms that mediate DAT endocytic recycling following constitutive and regulated internalization. In addition to shedding light on this critical process, these findings resolve conflict among multiple, seemingly disparate, previous reports on DAT's postendocytic fate.

## Introduction

Dopamine (DA) neurotransmission is required for vital functions in the CNS, including locomotion, reward, and sleep/arousal (Iversen

and Iversen, 2007). Dysregulated DA neurotransmission is linked to multiple neurological and psychiatric disorders such as Par-

Received Dec. 20, 2016; revised July 17, 2017; accepted Aug. 19, 2017.

Author contributions: S.W., R.R.F., C.U., A.Y.T., and H.E.M. designed research; S.W. and R.R.F. performed research; A.Y.T. contributed unpublished reagents/analytic tools; S.W., R.R.F., L.M.L., K.E.F., and H.E.M. analyzed data; S.W., R.R.F., L.M.L., K.E.F., and H.E.M. wrote the paper.

This work was supported by the National Institutes of Health (Grants DA15169 and DA035224 to H.E.M.).

The authors declare no competing financial interests.

Correspondence should be addressed to Haley E. Melikian, Ph.D., Brudnick Neuropsychiatric Research Institute, Department of Psychiatry, University of Massachusetts Medical School, 303 Belmont Street, Worcester, MA 01604. E-mail: haley.melikian@umassmed.edu.

DOI:10.1523/JNEUROSCI.3885-16.2017

Copyright © 2017 the authors 0270-6474/17/379438-15\$15.00/0

kinson's disease, schizophrenia, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and bipolar disorder (Sawa and Snyder, 2002; Chen et al., 2004; Sulzer and Schmitz, 2007; Sharma and Couture, 2014). Following evoked DA release, extracellular DA is cleared rapidly via presynaptic reuptake, mediated by the plasma membrane DA transporter (DAT) (Gether et al., 2006; Torres and Amara, 2007). DAT is potently inhibited by addictive psychostimulants, such as cocaine and amphetamine, as well as by therapeutic drugs, such as methylphenidate (Ritalin) (Torres and Amara, 2007; Kristensen et al., 2011). Multiple DAT coding variants have been reported in ADHD, ASD, and infantile Parkinsonism, and these DAT mutants exhibit anomalous DA efflux, loss of function, or DAT membrane instability due to endocytic dysfunction (Mazei-Robison et al., 2008; Sakrikar et al., 2012; Hamilton et al., 2013; Bowton et al., 2014; Cartier et al., 2015). Therefore, DA homeostasis is exquisitely sensitive to altered DAT activity, and mechanisms that regulate DAT function and availability are predicted to significantly impact DA-dependent processes.

DAT surface expression is dynamically regulated by endocytic trafficking (Melikian, 2004; Eriksen et al., 2010; Bermingham and Blakely, 2016). DAT internalizes constitutively, and either acute PKC activation or amphetamine exposure accelerates DAT endocytosis, thereby decreasing DAT surface expression and function (Daniels and Amara, 1999; Melikian and Buckley, 1999; Saunders et al., 2000). Considerable effort has been directed toward understanding DAT's postendocytic fate. Multiple studies indicate that DAT recycles back to the plasma membrane under basal and regulated conditions (Loder and Melikian, 2003; Boudanova et al., 2008a; Furman et al., 2009b; Chen et al., 2010; Richardson et al., 2016). Paradoxically, DAT postendocytic tracking studies using either antibody feeding or fluorescent cocaine analogs to track DAT reported that DAT targets to prelysosomal and lysosomal pathways, not to classical recycling endosomes (Eriksen et al., 2009; Eriksen et al., 2010; Vuorenpää et al., 2016). In contrast, neuronal fractionation studies (Rao et al., 2011) and tracking studies in heterologous cells and primary cultured neurons suggest differential DAT targeting (Hong and Amara, 2013). Moreover, a recent antibody feeding study performed in acute mouse brain slices reported little surface DAT internalization in either DAergic terminals or somatodendritic compartments (Block et al., 2015). These conflicting reports have raised considerable debate among transporter biologists and have failed to identify the mechanism(s) that governs DAT's postendocytic fate.

The retromer complex mediates endosomal export of cargo destined for either retrograde transport to the trans-Golgi network (TGN), or for rapid recycling to the plasma membrane (Seaman, 2004; Burd and Cullen, 2014). Multiple neuronal proteins recycle via a retromer-dependent mechanism, including  $\beta$ 2-adrenergic receptors, ionotropic glutamate receptors, wntless, and Alzheimer-associated sortilin-related receptor 1 (Rogaeva et al., 2007; Zhang et al., 2012; Choy et al., 2014; Varandas et al., 2016). Moreover, retromer disruption is closely linked to multiple neurological disorders, including Alzheimer's and Parkinson's diseases (Muhammad et al., 2008; Tsika et al., 2014; Dhungel et al., 2015; Small and Petsko, 2015).

Previous discrepancies in DAT postendocytic mechanisms prompted us to investigate the DAT postendocytic itinerary in the absence of either bound ligands or antibodies, and to identify the molecular mechanisms governing DAT postendocytic sorting. In the current study, we took advantage of PRIME labeling (Uttamapinant et al., 2010) to covalently couple fluorophore to the DAT surface population and subsequently track DAT's

temporal-spatial postendocytic itinerary. Our results reveal a critical role for retromer in DAT endocytic trafficking and implicate the DAT carboxy-terminal PDZ-binding motif in retromer-mediated DAT recycling.

## Materials and Methods

**Materials.** Picolyl azide (pAz) and Bis[(tertbutyltriazoyl)methyl]-[(2-carboxymethyltriazoyl)methyl]-amine (BTAA) were synthesized as described previously (Uttamapinant et al., 2012). Rat anti-DAT antibody (MAB369) was from Millipore and mouse anti-actin antibody (sc-56459) was from Santa Cruz Biotechnology. Mouse anti-EEA1 (610456) and mouse anti-rab11 (610656) antibodies were from BD Transduction. Rabbit anti-rab7 antibody (D95F2) was from Cell Signaling Technology and goat anti-Vps35 antibody (NB100-1397) was from Novus Biologicals. Horseradish peroxidase-conjugated secondary antibodies were from Millipore (goat anti-rat), Jackson ImmunoResearch (donkey anti-goat), and Pierce (goat anti-mouse). Alexa Fluor-conjugated anti-rat, anti-mouse, and anti-rabbit secondary antibodies were from Invitrogen and donkey anti-goat Alexa Fluor 488 (minimal cross-reaction to mouse serum proteins) and donkey anti-rat Alexa Fluor 594 (minimal cross-reaction to mouse serum proteins) were from Jackson ImmunoResearch. Alkyne-Alexa Fluor 594 was from Invitrogen. [ $^3\text{H}$ ]DA (dihydroxyphenylethylamine 3,4-[ring-2,5,6- $^3\text{H}$ ]) was from PerkinElmer. Sulfo-NHS-SS-biotin, Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and streptavidin agarose were from Thermo Fisher Scientific. Phorbol 12-myristate 13-acetate (PMA), AIM-100,  $\beta$ -CFT (WIN35428), and GBR12909 were from Tocris Bioscience. All other chemicals and reagents were from Thermo Fisher Scientific or Sigma-Aldrich and were of highest grade possible.

**cDNA constructs and mutagenesis.** To generate ligase acceptor peptide (LAP)-hDAT-pcDNA3.1(+), hDAT was subcloned into pBS-SKII<sup>-</sup> as a shuttle vector and degenerate mutations were introduced into hDAT codons corresponding to amino acids 193 and 204, adding BsaBI and HpaI sites (Quikchange mutagenesis kit; Agilent Technologies). Sense and antisense oligonucleotides encoding the LAP-peptide sequence, flanked by linkers (GSSGSSGGFEIDKVVHDFPAGSSGSSG; LAP peptide sequence is underlined), were annealed and ligated into the blunt BsaBI/HpaI site, and the final LAP-DAT cDNA was excised subcloned into pcDNA3.1(+) at HindIII/XbaI sites. LAP-DAT-AAA-pcDNA3.1(+) was generated by mutating the last three amino acids of hDAT into alanines (LKV to AAA) using Quikchange mutagenesis kit (Agilent Technologies). All DNA sequences were determined by the dideoxy chain termination (Genewiz).

**Cell culture and transfections.** The rat mesencephalic cell line 1Rb3AN27 was kindly provided by Dr. Alexander Sorkin (University of Pittsburgh, Pittsburgh, PA) and maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM glutamine, and 100 units/ml penicillin/streptomycin at 37°C and 5% CO<sub>2</sub>. Pooled, stable AN27 cell lines expressing wild-type hDAT, LAP-hDAT, or LAP-hDAT-AAA were generated by transfecting  $2 \times 10^5$  cells/well in 6-well culture plate with 1  $\mu\text{g}$  of plasmid DNA using Lipofectamine 2000, at a lipid: DNA ratio of 2:1 (w/w). Stably transfected cells were selected with 200  $\mu\text{g}/\text{ml}$  G418 (Invitrogen) and resistant cells were trypsinized, pooled, and maintained under selective pressure in 80  $\mu\text{g}/\text{ml}$  G418. SK-N-MC cells were from the American Type Culture Collection and were maintained in MEM (Sigma-Aldrich M2279) supplemented with 10% fetal bovine serum (Invitrogen), 2 mM L-glutamine,  $10^2$  U/ml penicillin/streptomycin at 37°C and 5% CO<sub>2</sub>. Pooled #14 stable SK-N-MC cell lines expressing hDAT were generated by transfecting  $1 \times 10^6$  cells/well in 6-well culture plate with 3  $\mu\text{g}$  of plasmid DNA using Lipofectamine 2000 at a lipid: DNA ratio of 2:1 (w/w). Stably transfected cells were selected in 500  $\mu\text{g}/\text{ml}$  G418 (Invitrogen) and resistant cells were pooled and maintained under selective pressure in 200  $\mu\text{g}/\text{ml}$  G418.

**[ $^3\text{H}$ ]DA uptake assay.** Cells were seeded onto 96-well plates 1 d before performing assays at  $2 \times 10^4$  or  $7.5 \times 10^4$  cells per well for single-point and kinetic studies, respectively. Cells were washed twice with KRH buffer containing the following (in mM): 120 NaCl, 4.7 KCl, 2.2 CaCl<sub>2</sub>, 1.2 MgSO<sub>4</sub>, 1.2 KH<sub>2</sub>PO<sub>4</sub>, and 10 HEPES, pH 7.4, and preincubated in KRH

buffer supplemented with 0.18% glucose at 37°C for 30 min in the presence of either vehicle or the indicated drugs. For single-point assays, uptake was initiated by adding 1  $\mu\text{M}$  [ $^3\text{H}$ ]DA in KRH buffer supplemented with 0.18% glucose and 10  $\mu\text{M}$  each pargyline and sodium ascorbate (KRH/g/p/a). For uptake kinetics, 10 $\times$  mixtures were prepared by diluting a 1/20<sup>th</sup> volume [ $^3\text{H}$ ]DA into 60  $\mu\text{M}$  unlabeled DA KRH/g/p/a. The 60  $\mu\text{M}$  [ $^3\text{H}$ ]DA solution was serially diluted into KRH/g/p/a to generate [ $^3\text{H}$ ]DA cocktails at 10 $\times$  the indicated final substrate concentrations. Cells were preincubated (20 min at 37°C) with KRH buffer supplemented with 0.18% glucose (KRH/g) and uptake was initiated by adding a 1/10 volume of 10 $\times$  concentrated [ $^3\text{H}$ ] substrate mixture. Non-specific uptake at each DA concentration was defined in parallel in the presence of 10  $\mu\text{M}$  GBR12909. Assays proceeded for 10 min at 37°C and were terminated by washing cells rapidly three times with ice-cold KRH buffer. Cells were solubilized in scintillation fluid and accumulated radioactivity was measured by liquid scintillation counting in a Wallac Microbeta plate counter.

**Endocytic rate measurements by reversible biotinylation.** Cells were plated at  $3 \times 10^5$  cells per well in 6-well plate 24 h before conducting experiments. Cells were washed three times with ice-cold PBS, pH 7.4, supplemented with 1 mM  $\text{MgCl}_2$  and 0.1 mM  $\text{CaCl}_2$  ( $\text{PBS}^{2+}$ ); surface proteins were biotinylated twice, 15 min at 4°C with 2.5 mg/ml sulfo-NHS-SS-biotin and quenched twice for 15 min at 4°C with 100 mM glycine/ $\text{PBS}^{2+}$  (quench solution). Internalization was initiated by washing cells rapidly three times with prewarmed (37°C)  $\text{PBS}^{2+}$  supplemented with 0.18% glucose/0.1% IgG/protease-free BSA ( $\text{PBS}^{2+}$ /g/BSA) containing either vehicle or the indicated drugs, and incubating for 10 min at 37°C. Zero time point and strip controls were kept at 4°C in parallel. Endocytosis was arrested by washing cells rapidly with ice-cold NT buffer (150 mM NaCl, 20 mM Tris, pH 8.6, 1.0 mM EDTA, pH 8.0, 0.2% protease free/IgG free BSA). Residual surface biotin was stripped by reducing twice with 100 mM TCEP in NT buffer for 25 min at 4°C, followed by 3 washes with  $\text{PBS}^{2+}$ . Cells were lysed in RIPA containing protease inhibitors for 20 min at 4°C with constant shaking and insoluble cellular debris was pelleted at 14,000  $\times$  g for 10 min at 4°C. Lysate protein concentrations were determined by BCA protein assay (Thermo Fisher Scientific), compared with BSA standards, and biotinylated proteins were isolated from equivalent amounts of total cellular protein by batch streptavidin-agarose affinity chromatography as described previously (Loder and Melikian, 2003; Holton et al., 2005; Boudanova et al., 2008a; Boudanova et al., 2008b; Gabriel et al., 2013; Wu et al., 2015). Samples were resolved by SDS-PAGE and DAT was detected by immunoblot using a monoclonal rat anti-DAT antibody (MAB369; Millipore). Non-saturating DAT bands were detected using a VersaDoc gel documentation system and were quantified using Quantity One software (Bio-Rad). Relative internalization rates were calculated as a percentage of biotinylated DAT internalized compared with DAT surface levels at  $t = 0$ .

**$^{37}\text{V}$ LplA expression and purification.** His<sub>6</sub>-tagged  $^{37}\text{V}$ LplA was expressed and purified as described previously (Uttamapinant et al., 2013). Briefly, pYFJ16-His<sub>6</sub>- $^{37}\text{V}$ LplA plasmid was transformed into BL21 *E. coli* and bacteria were incubated at 37°C with shaking until they attained log phase growth. Protein expression was induced with 100  $\mu\text{g}/\text{ml}$  isopropyl- $\beta$ -D-thiogalactopyranoside and proceeded for 8 h at room temperature. Bacteria were lysed and His<sub>6</sub>- $^{37}\text{V}$ LplA was purified by nickel-affinity chromatography. Eluted protein was dialyzed for 8 h twice against 20 mM Tris base, 1 mM DTT, 10% (v/v) glycerol, pH 7.5, at 4°C and protein concentrations were determined by  $A_{280}$  absorbance (Nano-Drop; Thermo Fisher Scientific) using an extinction coefficient of 46250  $\text{M}^{-1} \text{cm}^{-1}$ . Ligase aliquots were stored at  $-80^\circ\text{C}$ .

**PRIME labeling and postendocytic tracking studies.** Live AN27 cells stably expressing the indicated LAP-DAT constructs were covalently labeled with alkyne-Alexa Fluor 594 as described previously (Uttamapinant et al., 2010; Uttamapinant et al., 2013). Briefly, cells were seeded onto glass coverslips in 24-well plates at a density of  $8 \times 10^4$  cell/well 1 d before assaying. Cells incubated with a ligation mixture containing 10  $\mu\text{M}$   $^{37}\text{V}$ LplA, 200  $\mu\text{M}$  pAz, 1.0 mM ATP, and 5.0 mM  $\text{MgCl}_2$  in  $\text{PBS}/3\%$  BSA for 20 min at room temperature, followed by 3 washes with  $\text{PBS}^{2+}$ . A low  $\text{Cu}^{2+}$  click labeling solution containing 10 mM  $\text{CuSO}_4$ , 50 mM BTAA, and 100 mM sodium ascorbate and was prepared and incubated at room

temperature for 10 min in a closed tube. The labeling solution was diluted 200 $\times$  with  $\text{PBS}^{2+}$  (producing final concentrations of 50  $\mu\text{M}$   $\text{CuSO}_4$ , 250  $\mu\text{M}$  BTAA, and 500  $\mu\text{M}$  sodium ascorbate), supplemented with alkyne-Alexa Fluor 594 to a final concentration of 20  $\mu\text{M}$ , and incubated with cells for 10 min at room temperature. Cells were washed three times with room temperature  $\text{PBS}^{2+}$  and internalization was initiated by washing cells rapidly and incubating in prewarmed (37°C)  $\text{PBS}^{2+}$ /g/BSA containing the indicated drugs. Cells were fixed at the indicated postendocytic time points in 4% paraformaldehyde for 10 min at room temperature and subsequently blocked, permeabilized, and stained with indicated primary antibodies and Alexa Fluor 488-conjugated secondary antibodies as described previously (Navaroli et al., 2011). Note that all of the antibodies directed against endosomal markers were carefully vetted for specificity by their ability to recognize native and GFP-tagged proteins via immunoblot and by their ability to label GFP-tagged endosomal markers *in situ*. Dried coverslips were mounted in ProLong Gold with DAPI to stain nuclei and were cured thoroughly before performing imaging.

**Wide-field microscopy.** Cells were visualized with a Zeiss Axiovert 200M microscope using a 63 $\times$ , 1.4 numerical aperture (NA) oil-immersion objective and 0.2  $\mu\text{m}$  optical sections were captured through the  $z$ -axis with a Retiga-1300R or Retiga-R1 cooled CCD camera (Qimaging). 3D  $z$ -stack images were deconvolved with a constrained iterative algorithm using measured point spread functions for each fluorescent channel using Slidebook version 5.0 software (Intelligent Imaging Innovations). All representative images shown are single, 0.2  $\mu\text{m}$  planes through the center of each cell.

**Image processing for colocalization.** Given an unprocessed, multicolor, 3D image stack, the DAT image was used to identify an extracellular background region of interest for background fluorescence estimation and the range of contiguous optical sections ( $z$ -axis planes) containing in-focus DAT signal (i.e., the cell). The sample fields imaged were chosen to contain at least 1 extracellular region at least 5  $\mu\text{m}$  across. This background region was determined automatically by first taking the maximum intensity projection (in  $Z$ ) of the DAT stack. Then, the  $(x, y)$  position of the 2D region ( $x \pm \text{radius}$ ,  $y \pm \text{radius}$ ) having the lowest average intensity within this projection was saved. The radius used was nominally 20 pixels ( $\pm 2 \mu\text{m}$ ). For each of the color image stacks, at each  $z$  plane, the average intensity of this 2D region was subtracted from all pixels of the plane, leaving as positive signal the fluorescence greater than the extracellular background. The outline of the box containing this background region was superimposed on the DAT maximum projection image, as well as the maximum projections of the other color stacks, for visual inspection and verification before proceeding with the analysis.

The in-focus DAT data planes were also determined automatically, by first calculating the normalized total energy,  $\hat{E}$ , of each  $Z$  plane, defined as follows:

$$E(z) = (\sum \sum I([x, y], z)^2 - n(z) \cdot \bar{I}(z)^2) / (n(z) \cdot \bar{I}(z)^2)$$

and

$$\hat{E}(z) = (E(z) - E_{\min}) / (E_{\max} - E_{\min}).$$

where  $I([x, y], z)$  is the pixel intensity at position  $[x, y]$  in plane  $z$ ,  $\bar{I}(z)$  is the average intensity of plane  $z$ , and  $n(z)$  is the total number of pixels in plane  $z$ . Starting from the bottom of the stack (i.e., the first  $z$  plane) and moving up, the first in-focus plane  $z_{\text{bot}}$  was defined as the  $z$  plane where  $\hat{E}(z)$  exceeds  $\hat{E}_T = 0.5$ . Similarly, starting from the top (i.e., the last  $z$  plane) and moving down, the last in-focus plane  $z_{\text{top}}$  was where  $\hat{E}(z)$  exceeds the threshold  $\hat{E}_T$ . This was generally a conservative threshold, keeping a few out-of-focus planes at the top and the bottom. The planes  $z_{\text{bot}}$  to  $z_{\text{top}}$  were extracted from the background-corrected multicolor stacks for deconvolution. The point-spread function of the microscope system was determined from images of slides of four-color, 175 nm diameter beads (PS-Speck Microscope Point Source Kit; Thermo Fisher Scientific) All images were subjected to regularized, constrained, iterative deconvolution as described previously (Carrington et al., 1995) with the same smoothness parameter ( $\alpha = 5 \cdot 10^{-5}$ ) and integrated until the algo-



rithm reached convergence (0.001 level). All image processing was performed using custom software.

**Colocalization analysis.** All image analysis was performed using custom software. Restored images were first segmented via a manually set threshold to identify the signal in each independent channel. Each 3D restored image was projected (via maximum intensity projection) to 2D and then displayed to maximize contrast between signal and background. Three independent thresholds were then chosen for each image at low, medium, and high levels. The criteria used to define these thresholds were as follows: “low” allowed for some diffuse background signal within the cells, “medium” removed all the diffuse cellular signal, and “high” eliminated the margins of labeled structures. To avoid biasing the analysis, thresholds were chosen without knowledge of the experimental conditions of the image. All pixels above threshold in the 3D images were retained, whereas those below threshold were set to 0. DAT colocalization with the indicated proteins was calculated by counting the number of positive (>0) pixels in the 3D DAT image that were also positive in the corresponding position of the indicated 3D protein image and dividing by the total number of positive DAT pixels. Colocalization percentages were calculated at three different thresholds for each channel; however, the percentages calculated using the medium threshold were chosen for statistical analysis and data presentation. The low and high thresholds were used to evaluate whether conclusions drawn from the colocalization results at the medium thresholds varied dependent upon the threshold chosen. Comparison among these conditions revealed that relative changes in DAT/protein colocalization across a given time course were not dependent upon the threshold level chosen; rather, only the baseline ( $t = 0$ ) percent colocalization was affected by a given threshold level.

**Brain slice immunohistochemistry and confocal microscopy.** All animals were handled according to University of Massachusetts Medical School Institutional Animal Care and Use Committee Protocol A1506 (H.E.M.). Adult male C57/Blk6 mice were perfused transcardially with 4% paraformaldehyde and brains were removed and postfixed for 1 d at 4°C, followed by dehydration in PBS/30% sucrose at 4°C for 2–3 d. Then, 25  $\mu$ m coronal sections were taken through the striatum and midbrain using a sliding microtome (Leica) and slices were blocked in PBS with 0.2% Triton X-100, 5% normal donkey serum, and 1% H<sub>2</sub>O<sub>2</sub>. For DAT and Vps35 immunofluorescence, sections were coincubated overnight with rat anti-DAT (1:2000) and goat anti-Vps35 (1:500) in PBS with 0.2% Triton X-100, 5% normal donkey serum, and 1% H<sub>2</sub>O<sub>2</sub>. Slices were rinsed in PBS and incubated with donkey anti-goat and donkey anti-mouse Alexa Fluor (1:2000 each) for 1 h at room temperature. Unbound secondary antibodies were washed in PBS and slices were mounted onto glass slides, dried, and coverslipped in Prolong Gold mounting medium containing DAPI (Invitrogen). Images were acquired with a Leica TCS SP5 II laser scanning confocal microscope (Cell and Developmental Biology Core, University of Massachusetts Medical School) using either a 20 $\times$ , 0.7 NA (HCX PL APO CS 20.0  $\times$  0.70 IMM; Leica) or a 63 $\times$ , 1.4 NA oil-immersion (HCX PL APO CS 63.0  $\times$  1.40 OIL, Leica) objective. Then, 0.4  $\mu$ m optical sections were captured through the z-axis and 3D z-stack images were imported into ImageJ using the Bio-Format Importer plugin. All images shown are single, representative 0.4  $\mu$ m planes.

**Short hairpin RNA (shRNA), lentiviral production, and transduction.** Human Vps35-targeted shRNAs cloned into the pGIPZ lentiviral vector were from GE Healthcare Dharmacon and were purchased from the University of Massachusetts Medical School RNAi Core.

Full-length hairpin sequences were as follows: nonsilencing (Luciferase 693): TGCTGTTGACAGTGAGCGCTCTAAGAACGTTGTA-TTTATATAGTGAAGCCACAGATGTATATAAATACAACGTTCTTA-GATTGCCTACTGCCTCGGA; hVps35 sh#32: TGCTGTTGACAG-TGAGCGACTGACAGATGAGTTTGCTAAATAGTGAAGCCACAGATGTATTAGCAAACCTCATCTGTCAGGTGCCTACTGCCTCGGA.

Initial shRNA efficacies were determined by immunoblotting cell lysates obtained from HEK293T cells transiently transfected (Lipofectamine 2000) with the indicated pGIPZ-shRNA versus control plasmids. Replication incompetent lentiviral particles were produced as described previously (Wu et al., 2015) and titers were determined 48 h after transfection by counting GFP-positive cells in transduced HEK293T cells.

For lentiviral transduction,  $2.5 \times 10^5$  DAT SK-N-MC cells/well were seeded into 12-well plates 1 d before viral transduction and infected with 3 ml of the indicated crude lentivirus supplemented with 8  $\mu$ g/ml polybrene. Virus was removed 24 h after infection and replaced with medium supplemented with 1  $\mu$ g/ml puromycin to select transduced cells. Cells were assayed 96 h after infection.

**Endocytic recycling assay.** DAT delivery to the cell surface from endocytic compartments was measured using a continuous biotinylation assay, as described previously (Boudanova et al., 2008a). DAT-SK-N-MC cells were treated with the indicated lentiviral particles for 96 h at 37°C and surface DAT was biotinylated at 4°C as described above. Endocytic trafficking was initiated by washing cells rapidly 3 times in prewarmed PBS<sup>2+</sup>/g/BSA (37°C) and incubating in PBS<sup>2+</sup>/g/BSA containing 1.0 mg/ml NHS-SS-biotin at 37°C for the indicated times, to covalently couple biotin to proteins newly delivered to the plasma membrane. To compensate for NHS group hydrolysis, the biotinylation reagent was replenished after the initial 20 min incubation for the 30 and 45 min time point samples. Labeling was terminated by washing 3 times with ice-cold quench solution and residual biotinylation reagent was quenched by incubating twice with quench solution for 15 min at 4°C. Parallel samples were maintained at 4°C to define the baseline biotinylation level at  $t = 0$ . Cells were lysed and biotinylated proteins were separated from nonbiotinylated by batch streptavidin affinity chromatography, as described above. Supernatants were concentrated using Amicon Ultra spin concentrators with a 30 kDa molecular weight cutoff (Millipore) and both biotinylated and supernatant DAT fractions were detected by immunoblot. The percentage biotinylated DAT at each time point was calculated as follows:

$$\frac{\text{Biotinylated DAT}}{(\text{biotinylated DAT}) + (\text{nonbiotinylated DAT})} \times 100$$


Biotinylated DAT values at each time point were normalized to the baseline biotinylated DAT value determined at  $t = 0$  for each independent experiment. Time course data were fitted to a one-phase association kinetic equation as follows:

$$Y = Y_0 + (Y_{max} - Y_0) * (1 - e^{-k * x})$$

where  $K$  is the rate constant and tau is the time constant defined as  $1/k$ .

**Cell surface biotinylation.** DAT surface levels in SK-N-MC cells were determined by steady-state biotinylation as described previously (Navaroli et al., 2011; Gabriel et al., 2013; Wu et al., 2015). Briefly, after infection with the indicated lentiviral particles, cells were labeled twice for 15 min at 4°C with 1.0 mg/ml sulfo-NHS-SS-biotin in PBS<sup>2+</sup> and excess biotinylation reagent was quenched twice for 15 min at 4°C with PBS<sup>2+</sup>/100 mM glycine. Excess glycine was removed by washing 3 times in ice-cold PBS<sup>2+</sup> and cells were lysed in RIPA buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate) containing protease inhibitors. Lysates were cleared by centrifugation and protein concentrations were determined with the BCA protein assay kit (Pierce). Biotinylated proteins from an equivalent amount of cellular protein were recovered by batch streptavidin affinity chromatography (overnight at 4°C) and bound proteins were eluted in denaturing SDS-PAGE sample buffer for 30 min at room temperature with rotation. Samples were analyzed by SDS-PAGE and the indicated proteins were detected by immunoblotting with the indicated antibodies. Immunoreactive bands were detected with SuperSignal West Dura (Pierce) and captured using the VersaDoc Imaging station (Bio-Rad). Nonsaturating bands were quantified using Quantity One software (Bio-Rad).

**Statistical analysis.** Data are presented as means of results from each independent experiment  $\pm$  SEM, as indicated in figure legends. For experiments in which two conditions were compared, data were analyzed using an unpaired, two-tailed Student's  $t$  test. For experiments in which three or more conditions were evaluated, statistical significance was calculated using either a one-way or two-way ANOVA, followed by *post hoc* multiple-comparisons tests, as indicated in the figure legends. The initial slope for each time course was determined for data points between  $t = 0$  and the plateau, defined as the point after which no significant differ-



**Figure 1.** DAT expression, function, downregulation, and endocytosis tolerate LAP peptide incorporation into the second extracellular loop. **A**, DA uptake kinetics. Saturable DA uptake was measured in stable WT-DAT AN27 or LAP-DAT AN27 cells as described in the Materials and Methods. Average data are presented  $\pm$  SEM;  $n = 6$ . **B**, LAP-DAT expression and PKC-mediated downregulation. Top, Immunoblot analysis. Representative immunoblots characterizing WT-DAT and LAP-DAT expression in AN27 cells and actin loading controls. Arrows indicated mature, fully glycosylated (m) and immature, partially glycosylated (i), DAT species. Bottom: [ $^3$ H] DA uptake assay. Cells were treated  $\pm$  1  $\mu$ M PMA for 30 min at 37°C and [ $^3$ H] DA uptake was measured with 1  $\mu$ M DA, as described in the Materials and Methods. Average data are expressed as a percentage of vehicle-treated controls  $\pm$  SEM. \*\*Significant compared with vehicle-treated control,  $p < 0.01$ , Student's  $t$  test,  $n = 4$ . **C**, Internalization assay. WT-DAT and LAP-DAT internalization rates were measured in AN27 cells  $\pm$  20  $\mu$ M AIM-100, as described in the Materials and Methods. Top, Representative immunoblots showing the total surface protein at  $t = 0$  (T), strip controls (S), and internalized protein during either vehicle (V), or AIM-100 (A) treatments. Bottom, Average internalization rates are presented as the percentage of vehicle-treated controls  $\pm$  SEM. \*Significantly greater than vehicle control,  $p < 0.05$ , one-tailed Student's  $t$  test,  $n = 6-10$ . **D**, PRIME strategy for labeling surface DAT. A LAP was engineered into the DAT second extracellular loop. pAz was covalently bound to surface DAT encoding LAP peptide (LAP-DAT) via LplA-mediated coupling, followed by conjugation with alkyne-Alexa Fluor 594 via low-Cu $^{2+}$  click chemistry, resulting in a fluorescently labeled surface DAT population. **E**, LAP-DAT labeling. Stable LAP-DAT AN27 cells were labeled with alkyne-Alexa Fluor 594 (red) as described in Materials and Methods, followed by fixation and staining with anti-DAT antibody (green). Two representative fields are shown and all cells in the field are indicated by DAPI staining (blue).


ences were detected. Data from independent experiments were analyzed by linear regression and slope values were averaged. All statistical analyses were performed using GraphPad Prism 6.0 software.

## Results

### DAT expression, function, and trafficking tolerate LAP peptide incorporation into extracellular loop 2

Previous studies investigating DAT postendocytic trafficking relied primarily on either antibody feeding or DAT bound to fluorescent cocaine analogs, either of which have potential to target DAT's postendocytic destination(s) artifactually. We sought to track DAT endocytic trafficking by covalently labeling the DAT cell surface population with small fluorophores, thereby creating a "fluorescent DAT." To accomplish this, we took advantage of the recently reported PRIME labeling approach (Uttamapinant et al., 2013). This method covalently couples fluorophore to cell surface proteins that encode an extracellular ligase acceptor peptide (LAP), which is a substrate for bacterial lipoic acid ligase (LplA). To generate a DAT construct compatible with extracellular LAP labeling, we replaced hDAT second extracellular loop (EL2) residues 193–204 with a 27 aa peptide that encodes the 13 aa LAP sequence flanked by linkers of 7 aa in length (LAP-DAT).

We first tested whether the LAP peptide insertion had any deleterious effect on DAT expression, function, functional downregulation, or regulated endocytosis when stably expressed in the rat mesencephalic cell line 1Rb3AN27 (AN27). LAP-DAT exhibited robust, saturable [ $^3$ H]DA uptake in these cells (Fig. 1A) and kinetic analyses revealed no significant difference between LAP-DAT and wild-type DAT (WT-DAT)  $V_{max}$  values (WT-DAT:  $99.3 \pm 18.2$  vs LAP-DAT:  $94.4 \pm 19.7$  pmol/min/mg;  $p = 0.86$ , Student's  $t$  test,  $n = 6$ ) or affinity for DA ( $K_m$ : WT-DAT  $2.8 \pm 0.4$  vs LAP-DAT  $4.8 \pm 1.3$   $\mu$ M;  $p = 0.17$ , Student's  $t$  test,  $n = 6$ ). Immunoblot analysis revealed that LAP-DAT expressed at levels comparable to WT-DAT, with a similar ratio of mature ( $\sim$ 75 kDa) to immature ( $\sim$ 55 kDa) biosynthetic species (Fig. 1B, top). LAP-DAT was also subject to PKC-induced function downregulation comparable to WT-DAT. PKC activation with PMA decreased WT-DAT and LAP-DAT function significantly to  $68.7 \pm 3.4\%$  and  $58.2 \pm 7.5\%$  control levels, respectively (Fig. 1B, bottom). We next tested whether LAP-DAT constitutively internalized and was subject to stimulated endocytosis in response to Ack1 inhibition, as we reported previously (Wu et al., 2015). Basal LAP-DAT internalization rates were not significantly dif-



**Figure 2.** LAP-DAT labeling facilitates DAT postendocytic tracking. **A**, Strategy for tracking DAT postendocytic routes using PRIME labeling. Live LAP-DAT AN27 cells were labeled via PRIME labeling at room temperature, as described in the Materials and Methods. Internalization was induced by shifting cells to  $37^{\circ}\text{C} \pm 20 \mu\text{M}$  AIM-100. Cells were then fixed at the indicated time points, permeabilized, and stained for EEA1. **B**, DAT trafficking to EEA1-positive early endosomes. Representative images of LAP-DAT (red) and the early endosome marker EEA1 (green) are shown at the indicated time points (note: vehicle-treated cells are shown). **C**, Average data expressed as the percentage of DAT colocalized with EEA1  $\pm$  SEM. Asterisks indicate significant differences,  $**p < 0.005$ ,  $***p < 0.001$ , two-way ANOVA with Bonferroni's multiple-comparisons test,  $n = 19$ –49 cells at each time point imaged across three independent experiments.


ferent from WT-DAT ( $p = 0.20$ ), and AIM-100 treatment increased both LAP-DAT ( $134.5 \pm 5.3\%$  control levels) and WT-DAT ( $162.6 \pm 16.8\%$  control levels) internalization significantly (Fig. 1C). Therefore, appending the DAT EL2 domain with the LAP peptide did not affect DAT biosynthesis, function, or regulated endocytosis, which is consistent with previous studies in which epitopes were engineered into EL2 (Sorkina et al., 2006; Navaroli et al., 2011). It should be noted, however, that, although LAP-DAT expression and function were comparable to WT-DAT in AN27 cells, we observed marked LAP-DAT proteolytic cleavage when expressed in either SK-N-MC or SH-SY5Y cells (data not shown), precluding use of these cells for LAP-DAT studies.

We next tested whether LAP-DAT could be covalently coupled to fluorophore using the PRIME strategy (see schematic; Fig. 1D) by coupling alkyne-Alexa Fluor 594 to LAP-DAT AN27 cells and subsequently fixing, permeabilizing, and costaining cells with an anti-DAT antibody. Alkyne-Alexa Fluor 594 signal was detected at the surface of cells expressing LAP-DAT, whereas nearby nontransfected cells (identified using DAPI staining) were not labeled (Fig. 1E). Moreover, the alkyne-Alexa Fluor 594 signal overlapped with the anti-DAT antibody signal at the cell surface. These results demonstrate that PRIME labeling is both highly efficacious and specific for LAP-DAT. As a negative control, we performed PRIME labeling on cells expressing WT-DAT and observed no labeling (data not shown). We observed that a linker between the DAT polypeptide backbone and the LAP peptide was absolutely required to achieve high-efficiency labeling and earlier attempts at labeling LAP-DAT constructs, either without linkers or with shorter linkers, failed to label cells efficiently (data not shown).

### Tracking DAT temporal-spatial postendocytic trafficking via PRIME labeling

We next used LAP-DAT to temporally and spatially track DAT's postendocytic fate. We labeled the DAT surface population at room temperature ( $18$ – $22^{\circ}\text{C}$ ; conditions of minimal endocytosis), stimulated internalization by shifting cells to  $37^{\circ}\text{C}$ , and then fixed/stained cells at various postendocytic time points to quantify DAT colocalization with several endosomal markers (see schematic; Fig. 2A). As a proof of concept, we first characterized DAT trafficking from the plasma membrane to early endosomes, given consistent reports that DAT colocalizes to EEA1/rab5-positive vesicles shortly after internalization (Daniels and Amara, 1999; Melikian and Buckley, 1999; Eriksen et al., 2009). At the 0 min time point,  $4.0 \pm 0.2\%$  of the LAP-DAT signal colocalized with EEA1 (Fig. 2B,C). This minimal colocalization was observed between DAT and each of the endocytic markers investigated throughout our study and we attributed this baseline signal to low-level DAT internalization that occurred during the room temperature labeling procedure. Under basal conditions, DAT/EEA1 colocalization increased rapidly and significantly over the first 10 min of internalization and peaked at  $21.3 \pm 1.4\%$  colocalization, which translates to a 430.9% enhancement over baseline. DAT/EEA1 colocalization plateaued at subsequent time points, although there was a trend for decreased DAT/EEA1 colocalization at the 60 min time point (Fig. 2C;  $p = 0.08$ ). We also observed significant, time-dependent DAT/EEA1 colocalization upon stimulating DAT internalization with  $20 \mu\text{M}$  AIM-100 (Fig. 2C). However, we observed a significant decrease in the initial slope of DAT/EEA1 colocalization over time in cells treated with AIM-100 compared with vehicle-treated cells (initial slope = vehicle:  $1.7 \pm 0.4$  vs AIM-100:  $0.87 \pm 0.1$ ,  $p =$





**Figure 3.** DAT targets to rab11- and rab7-positive endosomes in PRIME labeling studies. Live LAP-DAT AN27 cells were labeled via PRIME labeling at room temperature, internalized for the indicated times at 37°C, and probed for either rab7 or rab11 as described in the Materials and Methods. **A, C**, Representative images showing LAP-DAT (red) with recycling endosome marker rab11 (green, **A**) or late endosome marker rab7 (green, **C**) at the indicated time points. **B, D**, Average data expressed as the percentage of DAT colocalized with either rab11 (**B**) or rab7 (**D**)  $\pm$  SEM. Asterisks indicate significant differences, \* $p < 0.05$ , \*\* $p < 0.005$ , \*\*\* $p < 0.001$ , two-way ANOVA with Bonferroni's multiple-comparisons test,  $n = 28$ –30 cells at each time point imaged over three independent experiments.


0.02, Student's  $t$  test,  $n = 30$ ; Fig. 2C). These results demonstrate that the PRIME labeling strategy is effective for tracking DAT from the cell surface to endosomal destinations. Note that, in the interest of space, we have only presented DAT internalization images under control conditions because any AIM-100-induced differences are not discernible by visual inspection alone.

After internalization and localization to early endosomes, proteins are targeted to degradative, recycling, or retrograde (i.e., TGN) pathways. Given that DAT recycling and rapid delivery to the plasma membrane has been reported by us and others (Loder and Melikian, 2003; Lee et al., 2007; Gabriel et al., 2013; Richardson et al., 2016), we next investigated whether DAT targets to the classic rab11 recycling endosome (Welz et al., 2014). Under basal conditions, we observed no significant DAT/rab11 colocalization over baseline at either the 5 or 10 min time points (Fig. 3A, B). A small, but statistically significant, increase in DAT/rab11 colocalization ( $7.4 \pm 0.42\%$ ) was observed at 20 min after endocytosis, which translated to 46.3% over baseline. During AIM-100 treatment, we observed significant increases in DAT/rab11 colocalization at 45 and 60 min time points and significantly more LAP-DAT colocalized with rab11 during AIM-100 treatment compared with control cells at the 60 min time point (Fig. 3B). These results indicate that although the majority of DAT does not traverse the conventional recycling pathway, a small but significant DAT population enters rab11-positive endosomes and this is increased when DAT endocytosis is stimulated by acute Ack1 inhibition.

Given that the majority of internalized DAT did not colocalize with rab11-positive endosomes, we next investigated whether DAT targeted to degradative endosomes by staining late endosomes using rab7 as a marker. Under basal conditions, DAT exhibited a slow, linear ( $r^2 = 0.95$ ) increase in rab7 colocalization over time, with  $22.1 \pm 0.97\%$  DAT/rab7 colocalization observed at the 45 min time point, which translated to a 295.5% elevation over baseline (Fig. 3C, D). AIM-100 treatment had no effect on the rate of DAT/rab7 colocalization (slope = vehicle:  $0.34 \pm 0.04$  vs AIM-100:  $0.31 \pm 0.04$ ,  $p = 0.62$ , Student's  $t$  test,  $n = 30$ ). These results suggest that a fraction of DAT moves slowly into rab7-positive endosomes after internalization, with no kinetic difference in late endosome targeting during basal versus stimulated DAT endocytic conditions.

#### DAT targets to retromer-positive endosomes

Given that DAT expression is quite stable, we questioned whether DAT postendocytic sorting to a rab7-positive compartment was indicative of immediate postendocytic targeting to the degradative pathway, or to another rab7-positive endosomal population. Recent studies indicate that rab7 is also part of the cargo-selective trimer (Vps35-Vps29-Vps26) that recruits proteins to the retromer complex from the endosomal membrane (Rojas et al., 2008; Seaman et al., 2009). Therefore, we hypothesized that DAT may recycle to the plasma membrane via a retromer-mediated mechanism. To test this possibility, we examined whether internalized DAT entered a retromer-positive endosome, as indicated by co-




**Figure 4.** DAT targets to retromer-positive endosomes. *A, B*, PRIME labeling studies. Surface DAT was coupled to Alexa594 via PRIME labeling, as described in the Materials and Methods, and DAT/Vps35 colocalization was determined at the indicated postendocytic time points. *A*, Representative images showing LAP-DAT (red) and retromer marker Vps35 (green) at the indicated time points. *B*, Average data expressed as the percentage of DAT-positive objects that colocalized with Vps35 signal  $\pm$  SEM. All later time points were significant different from baseline; Asterisks indicate significant differences, \* $p < 0.05$ , \*\* $p < 0.001$ , two-way ANOVA with Bonferroni's multiple-comparisons test,  $n = 24$ – $30$  cells imaged at each time point imaged over three independent experiments. *C, D*, DAT/Vps35 colocalization in mouse DAergic neurons. Coronal sections were prepared from mouse brains and were costained for DAT and Vps35 and imaged as described in the Materials and Methods. *C*, Representative single-plane confocal images showing DAT (red) and Vps35 (green) expression in somatodendritic region of the substantia nigra. Scale bar,  $50 \mu\text{m}$  (top) and  $1 \mu\text{m}$  (bottom). *D*, Representative confocal images showing DAT (red) and Vps35 (green) staining in dorsal striatum. Scale bar,  $5 \mu\text{m}$ . White arrowheads indicate DAT/Vps35 colocalized puncta.

localization with Vps35, a retromer core protein required for cargo recruitment into retromer (Seaman, 2004; Burd and Cullen, 2014). Under basal conditions, we observed DAT/Vps35 colocalization that increased rapidly and significantly over the first 15 min of internalization, and peaked at  $24.0 \pm 0.88\%$  colocalization, which translates to  $413.0\%$  enhanced colocalization over baseline (Fig. 4*A, B*). We further observed a significant loss in DAT/Vps35 colocalization at 45 min compared with the 15 min peak, likely reflecting DAT exiting from Vps35-positive endosomes over time. During AIM-100 stimulation, DAT/Vps35 colocalization likewise increased significantly over time (Fig. 4*B*). However, AIM-100 treatment diminished the rate of increase in DAT/Vps35 colocalization significantly compared with vehicle-treated cells (initial slope = vehicle:  $1.2 \pm 0.30$  vs AIM-100:  $0.63 \pm 0.10$ ,  $p = 0.04$ , Student's *t* test,  $n = 24$ – $30$ ) and peaked at 30 min postinternalization (Fig. 4*B*). We further observed no significant loss of DAT/Vps35 colocalization after the 30 min peak. These results suggested that DAT is targeted to the retromer complex after either basal or stimulated endocytosis and is recruited away from retromer-positive endosomes over time under basal conditions.

We next investigated whether native DAT colocalized with Vps35 in bona fide DAergic neurons. Immunocytochemistry performed on coronal mouse brain slices revealed DAT/Vps35 colocalization in perinuclear regions of substantia nigra DAergic neurons (Fig. 4*C*). We also observed discrete DAT/Vps35-positive colocalized puncta in a subset of DAergic terminals in the dorsal striatum (Fig. 4*D*), consistent with DAT targeting to retromer complex. We also attempted to use PRIME labeling in *ex vivo* mouse striatal slices to track DAT postendocytic trafficking in native DAergic terminals. We engineered an AAV construct encoding a DIO-HA-tagged LAP-DAT and packaged this construct into AAV2 particles. These were injected stereotaxically into DAT<sup>IRES-Cre</sup> mouse midbrain to facilitate HA-LAP-DAT expression exclusively in dopaminergic neurons. HA-LAP-DAT expressed and was targeted robustly to DAergic terminals in the dorsal striatum (data not shown). However, we were unable to label LAP-DAT efficiently in *ex vivo* striatal slices prepared from injected mice. Together with our cellular LAP-DAT studies and mouse striatal immunocytochemistry, these results indicate that DAT targets to retromer in both AN27 cells and intact DA neu-






**Figure 5.** Retromer complex is required for DAT recycling and to maintain DAT surface expression. Lentiviral-mediated hVps35 knockdown in SK-N-MC cells. DAT SK-N-MC cells were transduced with the indicated lentiviral particles, as described in the Materials and Methods and assays were performed 96 h after transduction. **A**, Vps35 knockdown efficiency. Top, Representative immunoblots of lysates from DAT-SK-N-MC cells transduced with lentiviral particles expressing pGIPZ vector (vec), nonsilencing shRNA (NS), or hVps35 #32 shRNA (#32), probed for Vps35 and actin. Bottom, Average hVps35 protein levels expressed as the percentage of vector-transduced hVps35 levels  $\pm$  SEM. \*\*\*\*Significantly different from vector control,  $p < 0.001$ , one-way ANOVA with Dunnett's *post hoc* analysis,  $n = 7$ . n.s., Not significant. **B**, DAT surface levels. DAT-SK-N-MC cells were transduced with the indicated lentiviral particles and DAT surface levels were measured by surface biotinylation, as described in the Materials and Methods. Top, Representative immunoblots showing the biotinylated DAT surface fraction and actin loading controls. Bottom, Average DAT surface levels (normalized to actin) expressed as the percentage of vector controls  $\pm$  SEM. \*\*\*Significantly different from vector control,  $p < 0.005$ , one-way ANOVA with Bonferroni's multiple-comparisons test,  $n = 6$ . **C**, Total DAT expression. Total DAT levels were quantified by immunoblotting, normalizing to actin loading controls. Top, Representative immunoblots. Bottom, Average total DAT levels (normalized to actin) expressed as the percentage of vector levels  $\pm$  SEM. \*\*Significantly different from vector control,  $p < 0.01$ , one-way ANOVA with Bonferroni's multiple-comparisons test,  $n = 5$ . **D, E**, Endocytic recycling assay. DAT endocytic recycling rates were determined by continuous biotinylation, as described in the Materials and Methods. **D**, Representative DAT immunoblots of the biotinylated (biot) and nonbiotinylated (nonbiot) DAT fractions at the indicated time points for vector-treated and Vps35 shRNA#32-treated cells. Arrow indicates a low-molecular-weight DAT fragment. **E**, Average recycling data. Values are expressed as the percentage of total DAT biotinylated over time  $\pm$  SEM. Two-way ANOVA indicates significant effect of shRNA,  $p < 0.0001$ , \*\*Significantly greater than vector control,  $p < 0.0001$ , Sidak's multiple-comparisons test,  $n = 7-8$ .

rons, consistent with the premise that internalized DAT is sorted and recycled via a retromer-dependent mechanism.

### Retromer complex is required for DAT recycling

We next investigated whether retromer activity was required to recycle DAT back to the plasma membrane. We reasoned that if DAT recycling were retromer dependent, then retromer disruption would decrease the DAT recycling rate and potentially decrease DAT surface levels and target DAT to degradation in lieu of recycling. To test these hypotheses, we used shRNA to knockdown Vps35, an approach previously reported to disrupt retromer function (Choy et al., 2014; Varandas et al., 2016). For these studies, we turned to stably transfected DAT-SK-N-MC cells, in which DAT trafficking is indistinguishable from that observed in *ex vivo* mouse striatal slices (Gabriel et al., 2013; Wu et al., 2015). Moreover, this system enabled us to study WT-DAT (rather than LAP-labeled) and to make use of commercially available human-directed shRNA constructs targeting hVps35, whereas rat-directed shRNAs for use in AN27 cells are not commercially available. We screened several human Vps35-targeted shRNA

constructs and found that shRNA#32 reduced Vps35 expression significantly to  $35.2 \pm 4.8\%$  control Vps35 levels in DAT-SK-N-MC cells (Fig. 5A). Vps35 knockdown decreased both absolute DAT surface levels (normalized to actin,  $54.9 \pm 6.4\%$  control; Fig. 5B) and total DAT levels ( $54.4 \pm 4.7\%$  control; Fig. 5C) significantly, whereas nonsilencing lentiviral particles had no effect on DAT expression. To test whether DAT loss in response to retromer disruption was due to impaired endocytic recycling, we used a continuous biotinylation assay to measure DAT recycling rates. We observed robust DAT recycling in cells infected with control lentiviral particles (Fig. 5D, E). In contrast, Vps35 knockdown attenuated DAT recycling significantly, with a significant increase in the recycling tau value (vector:  $10.1 \pm 1.9$  vs shRNA#32:  $15.7 \pm 2.4$ ,  $p < 0.05$ , one-tailed Student's *t* test,  $n = 7-8$ ; Fig. 5E). Interestingly, although total DAT levels were diminished, the ratio of surface: intracellular DAT was significantly higher after Vps35 knockdown (Fig. 5E), suggesting that retromer disruption caused total DAT loss via enhanced postendocytic degradation. Indeed, we observed a low-molecular-weight DAT fragment in intracellular fractions (Fig. 5D) that was signif-



**Figure 6.** Cocaine accelerates DAT exit from retromer-positive endosomes in PRIME labeling studies. The DAT surface population was coupled to Alexa Fluor 594 via PRIME labeling, as described in the Materials and Methods, and DAT colocalization with either rab7 (**A**) or Vps35 (**B**) was measured at the indicated postendocytic time points,  $\pm 100 \mu\text{M}$  WIN35428 (**A**) or  $\pm 100 \mu\text{M}$  cocaine (**B**). Average data are presented. Two-way ANOVA revealed an interaction of both time ( $p < 0.0001$ ) and drug ( $p = 0.0018$ ). Asterisks denote significant differences between the indicated samples, Tukey's multiple-comparisons test,  $***p < 0.0001$ ,  $*p < 0.03$ ,  $n = 28$ –30 cells imaged over 3 independent experiments.

icantly enhanced after Vps35 knockdown, as normalized to mature intracellular DAT at the 0 min time point (vector:  $0.11 \pm 0.05$ ; shRNA#32:  $1.41 \pm 0.82$ ,  $p < 0.04$ , Student's *t* test,  $n = 3$ –5). Together, these results demonstrate that retromer is required to maintain DAT surface levels and supports that retromer is a major DAT recycling mechanism.

#### Effect of cocaine and cocaine analogs on DAT targeting and recycling

Given that previous reports found that cocaine increases DAT surface expression acutely (Daws et al., 2002; Little et al., 2002) and also that previous studies used high-affinity, fluorescent cocaine analogs to track DAT trafficking (Eriksen et al., 2009; Eriksen et al., 2010), we next tested whether either cocaine or high-affinity tropane analogs influence DAT trafficking to either prelysosomal or retromer-positive endosomes. As seen in Figure 6A, incubation with saturating concentrations of the high-affinity cocaine analog WIN35429 had no significant effect on the


slope of DAT targeting to rab7-positive endosomes (vehicle:  $0.19 \pm 0.05$ ; WIN35429:  $0.20 \pm 0.06$ ,  $p = 0.75$ , Student's *t* test,  $n = 30$  cells sampled over 3 independent experiments), suggesting that high-affinity tropanes do not enhance DAT targeting to degradation. We next tested whether cocaine binding to DAT influenced either targeting to or recruitment from retromer-positive endosomes. Under vehicle-treated conditions, and consistent with our initial findings (Fig. 4), DAT-Vps35 colocalization increased significantly over time, from 0 to 20 min post-endocytosis, and then decreased significantly from 20–45 min as DAT exited retromer-positive endosomes (Fig. 6B). In the presence of  $100 \mu\text{M}$  cocaine, DAT-Vps35 colocalization increased significantly from 0–10 min after endocytosis, with no significant difference in the initial rate of DAT entry into Vps35-positive endosomes compared with vehicle (slopes measured from 0–10 min: vehicle =  $1.7 \pm 0.2$ ;  $100 \mu\text{M}$  cocaine =  $1.9 \pm 0.4$ ,  $p = 0.55$ , Student's *t* test,  $n = 3$  independent assays with 28–30 total cells; Fig. 6B). However, during cocaine treatment, DAT/Vps35 colocalization plateaued by 20 min and then decreased significantly by 45 min (Fig. 6B). Moreover, cocaine treatment significantly decreased DAT/Vps35 colocalization at the 20 and 45 min post-endocytic time points, as compared to vehicle-treated controls (Fig. 6B). Given that cocaine did not alter targeting to degradative endosomes, these results suggest that cocaine may increase DAT recruitment out of retromer-positive endosomes and possibly increase DAT recycling, consistent with previous results demonstrating increased DAT surface expression after cocaine exposure (Daws et al., 2002; Little et al., 2002).

#### DAT exit from retromer is dependent upon its C-terminal PDZ-binding motif

We next investigated whether a specific domain either targeted DAT to and/or recruited DAT from retromer. Many cargo proteins are recruited to the retromer complex via PDZ-binding motifs (Lauffer et al., 2010; Clairfeuille et al., 2016; McGarvey et al., 2016). Interestingly, DAT encodes a C-terminal PDZ-binding motif (–LKV), and multiple reports indicate that DAT surface stability is dependent upon this motif (Torres et al., 2001; Bjerggaard et al., 2004; Rickhag et al., 2013). To test whether the DAT PDZ-binding motif is required for retromer-dependent recycling, we mutagenized the DAT C terminus within the LAP-DAT background, converting the –LKV motif to alanine residues (DAT-AAA), and tested whether DAT targeting to retromer-positive endosomes was affected. As seen in Figure 7, both WT-DAT and DAT-AAA targeted robustly to Vps35-positive endosomes and no significant differences were observed in their colocalization with Vps35 at either the  $t = 0$  or  $t = 20$  min time points (Fig. 7A,B). However, we observed significantly less WT-DAT/Vps35 colocalization compared with DAT-AAA at the 45 min time point, consistent with exit of WT-DAT, but not the DAT-AAA mutant, from retromer-positive endosomes. These data suggest that the DAT –LKV sequence may contribute to DAT exit from retromer-positive endosomes. To further test this possibility, we compared WT-DAT versus DAT-AAA recycling in AN27 cells (Fig. 7C,D). Interestingly, we observed a significant difference in recycling between WT-DAT and DAT-AAA and, in several experiments, DAT-AAA recycling failed to fit one-phase association kinetics, consistent with disrupted endocytic recycling.

#### Discussion

After biosynthesis in midbrain dopaminergic soma, DAT is forward trafficked to distant presynaptic boutons. Given the con-



**Figure 7.** DAT exit from retromer and recycling require a C-terminal PDZ-binding motif. **A, B,** PRIME labeling studies. WT-DAT and DAT-AAA surface populations were coupled to alkyne-Alexa Fluor 594 via PRIME labeling, as described in the Materials and Methods, and DAT/Vps35 localization was determined at the indicated postendocytic time points. **A,** Representative images showing WT-LAP-DAT or LAP-DAT-AAA (red) and retromer marker Vps35 (green) at the indicated time points. **B,** Average data expressed as the percentage of DAT-positive objects that colocalized with Vps35 signals  $\pm$  SEM. Asterisks indicate significant differences,  $*p < 0.04$ ,  $**p < 0.001$ , two-way ANOVA with Bonferroni's multiple-comparisons test,  $n = 29$ –30 cells imaged at each time point over three independent experiments. **C, D,** Endocytic recycling assay. DAT endocytic delivery to the plasma membrane was measured by continuous biotinylation in AN27 cells stably expressing either WT-LAP-DAT or LAP-DAT-AAA, as described in the Materials and Methods. **C,** Representative DAT immunoblots of the biotinylated (biot) and nonbiotinylated (nonbiot) DAT fractions at the indicated time points for WT-DAT (top) vs DAT-AAA (bottom). **D,** Average recycling data. Values are expressed as the percentage of total DAT biotinylated over time  $\pm$  SEM. Two-way ANOVA indicates a significant effect of DAT construct,  $p < 0.0003$ ,  $n = 7$ .

siderable energy expenditure that neurons invest to generate DAergic terminals, it is evolutionarily advantageous to maintain these complex structures. Endocytic recycling rapidly modulates synaptic function, bypassing the need for *de novo* biosynthesis. Multiple studies report that DAT undergoes constitutive and regulated internalization (Melikian, 2004; Bermingham and Blakely, 2016). However, DAT's postendocytic fate has long been debated, with numerous reports demonstrating functional DAT recycling (Loder and Melikian, 2003; Boudanova et al., 2008a; Chen et al., 2013; Richardson et al., 2016), whereas tracking studies observe DAT targeting to degradative vesicles (Miranda et al., 2005; Eriksen et al., 2010). These disparate findings may arise from methodological differences among the studies, which use either antibodies (Hong and Amara, 2013; Block et al., 2015) or fluorescent ligands (Eriksen et al., 2009) to interrogate DAT targeting. Although our approach using PRIME labeling is not likely to either perturb the DAT substrate-binding pocket or impose large steric hindrance on DAT, there is still the possibility that

appending DAT with a small fluorophore may influence its postendocytic fate.

Consistent with previous results, we observed robust, rapid DAT entry into EEA1-positive endosomes within 5–10 min after endocytosis. Rather than observing biphasic entry into and exit from these vesicles, we observed enhanced DAT/EEA1 colocalization that plateaued. This suggests that the DAT cell surface population did not internalize *en masse*. Rather, discrete DAT populations may internalize differentially over time, eventually redistributing labeled DAT throughout the endocytic pathway (Fig. 2C). Alternatively, DAT internalization may be a stochastic process; however, single-particle tracking studies would be required to test this possibility. Surprisingly, we observed a significantly slower initial rate of DAT/EEA1 colocalization during AIM-100-stimulated DAT internalization (Fig. 2C). Basal DAT internalization is clathrin and dynamin independent, whereas PKC- and AIM-100-stimulated DAT internalization are clathrin and dynamin dependent (Gabriel et al., 2013; Wu et al., 2015).



Therefore, a DAT subpopulation may target to EEA1-negative early endosomes (Hayakawa et al., 2006; Lakadamyali et al., 2006; Kalaidzidis et al., 2015) after stimulated endocytosis. Alternatively, stimulating DAT internalization may saturate the early endosomal machinery and stall entry kinetics into EEA1-positive early endosomes.

Although rab11-dependent DAT delivery to the plasma membrane has been reported (Loder and Melikian, 2003; Furman et al., 2009a; Sakrikar et al., 2012; Richardson et al., 2016), previous DAT tracking studies have not observed robust DAT entry into classic rab11-positive recycling endosomes (Eriksen et al., 2010; Hong and Amara, 2013). We observed a small, but significant, enhancement in DAT/rab11 colocalization over time under basal conditions and significantly increased DAT targeting to rab11-positive endosomes after stimulated endocytosis (Fig. 3A,B). However, DAT/rab11 colocalization was relatively modest over time (~46%), with kinetics that differed from DAT entry into early, EEA1-positive endosomes. In contrast, we observed robust and significant DAT colocalization in Vps35-positive vesicles, which peaked at 15–20 min after internalization (Fig. 4A,B), with 513% enhancement over baseline, comparable to that observed for DAT entry into early endosomes (~500% over baseline). These kinetic similarities suggest that the majority of internalized DAT targets to the retromer-positive endosomes. Retromer and rab11 dependence are not necessarily mutually exclusive because several studies report that rab11 may function in consort with retromer to facilitate recycling (van Weering et al., 2012; Hsiao et al., 2015). Likewise, several reports indicate that rab7 is required for retromer recruitment both in yeast and mammalian cells and acts in consort with rab5 (Rojas et al., 2008; Seaman et al., 2009). Thus DAT trafficking through rab7-positive endosomes is also consistent with a retromer-mediated mechanism. However, DAT movement into rab7-positive versus retromer-positive endosomes exhibited distinctly slower and linear kinetics, suggesting that a DAT subset consistently targets to a degradative pathway. Indeed, we observed a decrease in total and surface DAT in response to retromer disruption, consistent with targeted degradation. However, unlike previous reports (Miranda et al., 2005; Hong and Amara, 2013), we did not observe enhanced DAT targeting to rab7-positive endosomes after stimulated DAT internalization (Fig. 3C,D).

It was not feasible to use PRIME labeling to track DAT's endocytic fate in *ex vivo* striatal slices. One possible explanation for this obstacle is that the 38 kDa LplA may not be able to efficaciously penetrate a 300  $\mu\text{m}$  acute brain slice. A recent study similarly used antibody feeding to characterize DAT endocytic trafficking in a DAT knock-in mouse expressing an extracellular HA epitope, but found little antibody localization with endosomal markers in dopaminergic terminal regions (Block et al., 2015). It is possible that this result is due to challenges in permeating a relatively thick brain slice (1.0 mm) with a large (150 kDa), globular antibody, similar to our results with PRIME labeling. Moreover, it is unclear whether DAT bound to large Ig would reflect native DAT endocytic targeting accurately, particularly in light of recent studies demonstrating that antibody-bound membrane proteins target to degradation regardless of their endogenous endocytic routes (St Pierre et al., 2011; Bien-Ly et al., 2014). However, a recent antibody feeding study reported differential DAT targeting to degradation or recycling in response to PKC activation or AMPH exposure, respectively (Hong and Amara, 2013).

Although it was not technically feasible for us to track DAT trafficking in native preparations, robust perinuclear DAT/

Vps35 colocalization was readily apparent in DAergic soma. This could indicate potential DAT recycling in somatodendritic compartments. Alternatively, this may simply reflect close opposition between retrograde-targeted proteins and TGN-localized DAT undergoing biosynthesis. Although DAT expression is robust in DAergic terminal regions, we only detected DAT/Vps35 colocalization in a small subset of DAT puncta. Interestingly, elegant recent work from Sulzer and colleagues revealed that only a small fraction of depolarized DAergic terminals actually release DA (Pereira et al., 2016). Therefore, DAT recycling may only occur in the small subset of actively releasing terminals. Consistent with this premise, we observe somewhat modest, but significant, DAT surface expression loss after PKC activation in *ex vivo* mouse striatal slices (Gabriel et al., 2013), which might reflect larger losses in individual active boutons averaged across a more static DAT population in inactive DA terminals. Future studies should more clearly illuminate this possibility.

Although retromer complex was originally characterized as the machinery that recruits cargo destined for retrograde trafficking to the TGN (Seaman et al., 1997; Seaman et al., 1998), recent studies demonstrate that retromer plays a key role in endosomal recycling (Seaman, 2012; Choy et al., 2014). Importantly, retromer disruption via shRNA-mediated Vps35 knockdown resulted in marked DAT depletion from the plasma membrane and a significant decrease in the DAT recycling rate (Fig. 5). However, retromer disruption did not deplete DAT surface expression completely over a 96 h knockdown window and did not block recycling completely. Given that we only achieved a partial Vps35 knockdown, there was likely still some active retromer complex available. Moreover, given that some DAT targets to rab11-positive endosomes, there may have remained some additional, compensatory retromer-independent recycling via a rab11-mediated mechanism.

Retromer-mediated cargo recruitment frequently requires interaction of sorting nexin 27 with a PDZ-binding motif on cargo proteins (Lauffer et al., 2010). DAT encodes a distal C-terminal PDZ binding motif (–LKV) and previous studies implicate this motif in stabilizing mature DAT in DAergic terminals (Torres et al., 2001; Bjerggaard et al., 2004; Rickhag et al., 2013). We found that DAT required the –LKV signal to exit from Vps35-positive endosomes and that mutagenizing this domain altered DAT recycling significantly, consistent with a role for this domain in retromer recruitment. Retromer-mediated endosomal fission in yeast requires Vps1, the yeast dynamin homolog (Chi et al., 2014; Arlt et al., 2015). Interestingly, we reported previously that DAT recycling relies upon a dynamin-dependent mechanism (Gabriel et al., 2013), also consistent with a retromer-mediated mechanism. Moreover, mutating the DAT carboxy-terminal PDZ binding motif reduced DAT surface expression in a mouse knock-in model and the dynamin K44A dominant-negative mutant partially rescued the surface loss of this mutant (Rickhag et al., 2013), suggesting that DAT-AAA is degraded postendocytically due to its inability to be recruited by retromer for recycling. Consistent with this possibility, GluT1 encodes a PDZ-binding domain required for recycling and retromer disruption drives GluT1 to degradation (Steinberg et al., 2013). Moreover, a recent interactome screen identified the DAT homolog GLYT2 (SLC6A9) as a retromer-associated protein (McMillan et al., 2016) and GLYT2 also encodes a carboxy-terminal PDZ binding motif that is required for stable plasma membrane expression (Armsen et al., 2007). In contrast, serotonin transporter expression and stability are insensitive to C-terminal perturbations (Schmid et al., 2001; El-Kasaby et al., 2010). It is also possible that other nearby resi-

dues affect DAT recruitment by retromer. Of particular potential interest is R615, particularly since a coding variant at this residue (R615C) was recently identified in an ADHD proband (Sakrikar et al., 2012). When characterized in cell lines, the R615C exhibits marked endocytic dysfunction, which can be rescued by coexpressing constitutively active Ack1 (Wu et al., 2015). Future studies evaluating potential R615C recruitment by retromer should shed significant light onto whether retromer-dependent DAT recycling may contribute to neuropsychiatric disorders.

## References

- Arlt H, Reggiori F, Ungermann C (2015) Retromer and the dynamin Vps1 cooperate in the retrieval of transmembrane proteins from vacuoles. *J Cell Sci* 128:645–655. [CrossRef Medline](#)
- Armsen W, Himmel B, Betz H, Eulenburg V (2007) The C-terminal PDZ-ligand motif of the neuronal glycine transporter GlyT2 is required for efficient synaptic localization. *Mol Cell Neurosci* 36:369–380. [CrossRef Medline](#)
- Birmingham DP, Blakely RD (2016) Kinase-dependent regulation of monoamine neurotransmitter transporters. *Pharmacol Rev* 68:888–953. [CrossRef Medline](#)
- Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, Luk W, Lu Y, Dennis MS, Weimer RM, Chung I, Watts RJ (2014) Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. *J Exp Med* 211:233–244. [CrossRef Medline](#)
- Bjerggaard C, Fog JU, Hastrup H, Madsen K, Loland CJ, Javitch JA, Gether U (2004) Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions. *J Neurosci* 24:7024–7036. [CrossRef Medline](#)
- Block ER, Nuttle J, Balcita-Pedicino JJ, Caltagareone J, Watkins SC, Sesack SR, Sorkin A (2015) Brain region-specific trafficking of the dopamine transporter. *J Neurosci* 35:12845–12858. [CrossRef Medline](#)
- Boudanova E, Navaroli DM, Melikian HE (2008a) Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent. *Neuropharmacology* 54:605–612. [CrossRef Medline](#)
- Boudanova E, Navaroli DM, Stevens Z, Melikian HE (2008b) Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization. *Mol Cell Neurosci* 39:211–217. [CrossRef Medline](#)
- Bowton E, Saunders C, Reddy IA, Campbell NG, Hamilton PJ, Henry LK, Coon H, Sakrikar D, Veenstra-VanderWeele JM, Blakely RD, Sutcliffe J, Matthies HJ, Erreger K, Galli A (2014) SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. *Transl Psychiatry* 4:e464. [CrossRef Medline](#)
- Burd C, Cullen PJ (2014) Retromer: a master conductor of endosome sorting. *Cold Spring Harb Perspect Biol* 6: pii: a016774. [CrossRef Medline](#)
- Carrington WA, Lynch RM, Moore ED, Isenberg G, Fogarty KE, Fay FS (1995) Superresolution three-dimensional images of fluorescence in cells with minimal light exposure. *Science* 268:1483–1487. [CrossRef Medline](#)
- Cartier E, Hamilton PJ, Belovich AN, Shekar A, Campbell NG, Saunders C, Andreassen TF, Gether U, Veenstra-Vanderweele J, Sutcliffe JS, Ulfrey-Reynolds PG, Erreger K, Matthies HJ, Galli A (2015) Rare autism-associated variants implicate syntaxin 1 (STX1 R26Q) phosphorylation and the dopamine transporter (hDAT R51W) in dopamine neurotransmission and behaviors. *EBioMedicine* 2:135–146. [CrossRef Medline](#)
- Chen NH, Reith ME, Quick MW (2004) Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. *Pflugers Arch* 447:519–531. [CrossRef Medline](#)
- Chen R, Furman CA, Gnegy ME (2010) Dopamine transporter trafficking: rapid response on demand. *Future Neurol* 5:123. [CrossRef Medline](#)
- Chen R, Daining CP, Sun H, Fraser R, Stokes SL, Leitges M, Gnegy ME (2013) Protein kinase C $\beta$  is a modulator of the dopamine D2 autoreceptor-activated trafficking of the dopamine transporter. *J Neurochem* 125:663–672. [CrossRef Medline](#)
- Chi RJ, Liu J, West M, Wang J, Odorizzi G, Burd CG (2014) Fission of SNX-BAR-coated endosomal retrograde transport carriers is promoted by the dynamin-related protein Vps1. *J Cell Biol* 204:793–806. [CrossRef Medline](#)
- Choy RW, Park M, Temkin P, Herring BE, Marley A, Nicoll RA, von Zastrow M (2014) Retromer mediates a discrete route of local membrane delivery to dendrites. *Neuron* 82:55–62. [CrossRef Medline](#)
- Clairefeuille T, Mas C, Chan AS, Yang Z, Tello-Lafos M, Chandra M, Widagdo J, Kerr MC, Paul B, Mérida I, Teasdale RD, Pavlos NJ, Anggono V, Collins BM (2016) A molecular code for endosomal recycling of phosphorylated cargos by the SNX27-retromer complex. *Nat Struct Mol Biol* 23: 921–932. [CrossRef Medline](#)
- Daniels GM, Amara SG (1999) Regulated trafficking of the human dopamine transporter: clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. *J Biol Chem* 274:35794–35801. [CrossRef Medline](#)
- Daws LC, Callaghan PD, Morón JA, Kahlig KM, Shippenberg TS, Javitch JA, Galli A (2002) Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. *Biochem Biophys Res Commun* 290: 1545–1550. [CrossRef Medline](#)
- Dhangel N, Eleuteri S, Li LB, Kramer NJ, Chartron JW, Spencer B, Kosberg K, Fields JA, Stafa K, Adame A, Lashuel H, Frydman J, Shen K, Masliah E, Gitler AD (2015) Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on alpha-synuclein. *Neuron* 85:76–87. [CrossRef Medline](#)
- El-Kasaby A, Just H, Malle E, Stolt-Bergner PC, Sitte HH, Freissmuth M, Kudlacek O (2010) Mutations in the carboxyl-terminal SEC24 binding motif of the serotonin transporter impair folding of the transporter. *J Biol Chem* 285:39201–39210. [CrossRef Medline](#)
- Eriksen J, Rasmussen SG, Rasmussen TN, Vaegter CB, Cha JH, Zou MF, Newman AH, Gether U (2009) Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs. *J Neurosci* 29:6794–6808. [CrossRef Medline](#)
- Eriksen J, Bjørn-Yoshimoto WE, Jørgensen TN, Newman AH, Gether U (2010) Postendocytic sorting of constitutively internalized dopamine transporter in cell lines and dopaminergic neurons. *J Biol Chem* 285: 27289–27301. [CrossRef Medline](#)
- Furman CA, Lo CB, Stokes S, Esteban JA, Gnegy ME (2009a) Rab 11 regulates constitutive dopamine transporter trafficking and function in N2A neuroblastoma cells. *Neurosci Lett* 463:78–81. [CrossRef Medline](#)
- Furman CA, Chen R, Guptaroy B, Zhang M, Holz RW, Gnegy M (2009b) Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy. *J Neurosci* 29:3328–3336. [CrossRef Medline](#)
- Gabriel LR, Wu S, Kearney P, Bellvé KD, Standley C, Fogarty KE, Melikian HE (2013) Dopamine transporter endocytic trafficking in striatal dopaminergic neurons: differential dependence on dynamin and the actin cytoskeleton. *J Neurosci* 33:17836–17846. [CrossRef Medline](#)
- Gether U, Andersen PH, Larsson OM, Schousboe A (2006) Neurotransmitter transporters: molecular function of important drug targets. *Trends Pharmacol Sci* 27:375–383. [CrossRef Medline](#)
- Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C, Belovich AN, Belovich AN, Sahai MA, Cook EH, Gether U, McHaurab HS, Matthies HJ, Sutcliffe JS, Galli A (2013) De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. *Mol Psychiatry* 18:1315–1323. [CrossRef Medline](#)
- Hayakawa A, Leonard D, Murphy S, Hayes S, Soto M, Fogarty K, Standley C, Bellve K, Lambright D, Mello C, Corvera S (2006) The WD40 and FYVE domain containing protein 2 defines a class of early endosomes necessary for endocytosis. *Proc Natl Acad Sci U S A* 103:11928–11933. [CrossRef Medline](#)
- Holton KL, Loder MK, Melikian HE (2005) Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. *Nat Neurosci* 8:881–888. [CrossRef Medline](#)
- Hong WC, Amara SG (2013) Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in dopamine neurons. *FASEB J* 27:2995–3007. [CrossRef Medline](#)
- Hsiao JC, Chu LW, Lo YT, Lee SP, Chen TJ, Huang CY, Ping YH, Chang W (2015) Intracellular transport of vaccinia virus in HeLa cells requires WASH-VPEF/FAM21-retromer complexes and recycling molecules Rab11 and Rab22. *J Virol* 89:8365–8382. [CrossRef Medline](#)
- Iversen SD, Iversen LL (2007) Dopamine: 50 years in perspective. *Trends Neurosci* 30:188–193. [CrossRef Medline](#)
- Kalaidzidis I, Miaczynska M, Brewińska-Olchowik M, Hupalowska A, Ferguson C, Parton RG, Kalaidzidis Y, Zerial M (2015) APPL endosomes are

- not obligatory endocytic intermediates but act as stable cargo-sorting compartments. *J Cell Biol* 211:123–144. [CrossRef Medline](#)
- Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, Strømgaard K, Gether U (2011) SLC6 neurotransmitter transporters: structure, function, and regulation. *Pharmacol Rev* 63:585–640. [CrossRef Medline](#)
- Lakadamyali M, Rust MJ, Zhuang X (2006) Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. *Cell* 124:997–1009. [CrossRef Medline](#)
- Laufer BE, Melero C, Temkin P, Lei C, Hong W, Kortemme T, von Zastrow M (2010) SNX27 mediates PDZ-directed sorting from endosomes to the plasma membrane. *J Cell Biol* 190:565–574. [CrossRef Medline](#)
- Lee FJ, Pei L, Moszczynska A, Vukusic B, Fletcher PJ, Liu F (2007) Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. *EMBO J* 26:2127–2136. [CrossRef Medline](#)
- Little KY, Elmer LW, Zhong H, Scheys JO, Zhang L (2002) Cocaine induction of dopamine transporter trafficking to the plasma membrane. *Mol Pharmacol* 61:436–445. [CrossRef Medline](#)
- Loder MK, Melikian HE (2003) The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. *J Biol Chem* 278:22168–22174. [CrossRef Medline](#)
- Mazei-Robison MS, Bowton E, Holy M, Schmudermaier M, Freissmuth M, Sitte HH, Galli A, Blakely RD (2008) Anomalous dopamine release associated with a human dopamine transporter coding variant. *J Neurosci* 28:7040–7046. [CrossRef Medline](#)
- McGarvey JC, Xiao K, Bowman SL, Mamonova T, Zhang Q, Bisello A, Sneddon WB, Ardura JA, Jean-Alphonse F, Vilardaga JP, Puthenveedu MA, Friedman PA (2016) Actin-sorting nexin 27 (SNX27)-retromer complex mediates rapid parathyroid hormone receptor recycling. *J Biol Chem* 291:10986–11002. [CrossRef Medline](#)
- McMillan KJ, Gallon M, Jellott AP, Clairfeuille T, Tilley FC, McGough I, Danson CM, Heesom KJ, Wilkinson KA, Collins BM, Cullen PJ (2016) Atypical parkinsonism-associated retromer mutant alters endosomal sorting of specific cargo proteins. *J Cell Biol* 214:389–399. [CrossRef Medline](#)
- Melikian HE (2004) Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation. *Pharmacol Ther* 104:17–27. [CrossRef Medline](#)
- Melikian HE, Buckley KM (1999) Membrane trafficking regulates the activity of the human dopamine transporter. *J Neurosci* 19:7699–7710. [Medline](#)
- Miranda M, Wu CC, Sorkina T, Korstjens DR, Sorkin A (2005) Enhanced ubiquitylation and accelerated degradation of the dopamine transporter mediated by protein kinase C. *J Biol Chem* 280:35617–35624. [CrossRef Medline](#)
- Muhammad A, Flores I, Zhang H, Yu R, Staniszewski A, Paniel E, Herman M, Ho L, Kreber R, Honig LS, Ganetzkly B, Duff K, Arancio O, Small SA (2008) Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. *Proc Natl Acad Sci U S A* 105:7327–7332. [CrossRef Medline](#)
- Navaroli DM, Stevens ZH, Uzelac Z, Gabriel L, King MJ, Lifshitz LM, Sitte HH, Melikian HE (2011) The plasma membrane-associated GTPase Rin interacts with the dopamine transporter and is required for protein kinase C-regulated dopamine transporter trafficking. *J Neurosci* 31:13758–13770. [CrossRef Medline](#)
- Pereira DB, Schmitz Y, Mészáros J, Merchant P, Hu G, Li S, Henke A, Lizardi-Ortiz JE, Karpowicz RJ Jr, Morgenstern TJ, Sonders MS, Kanter E, Rodriguez PC, Mosharov EV, Sames D, Sulzer D (2016) Fluorescent false neurotransmitter reveals functionally silent dopamine vesicle clusters in the striatum. *Nat Neurosci* 19:578–586. [CrossRef Medline](#)
- Rao A, Simmons D, Sorkin A (2011) Differential subcellular distribution of endosomal compartments and the dopamine transporter in dopaminergic neurons. *Mol Cell Neurosci* 46:148–158. [CrossRef Medline](#)
- Richardson BD, Saha K, Krout D, Cabrera E, Felts B, Henry LK, Swant J, Zou MF, Newman AH, Khoshbouei H (2016) Membrane potential shapes regulation of dopamine transporter trafficking at the plasma membrane. *Nat Commun* 7:10423. [CrossRef Medline](#)
- Rickhag M, Hansen FH, Sorensen G, Strandfelt KN, Andresen B, Gotfryd K, Madsen KL, Vestergaard-Klewe I, Ammendrup-Johnsen I, Eriksen J, Newman AH, Füchtbauer EM, Gomez J, Woldbye DP, Wörtwein G, Gether U (2013) A C-terminal PDZ domain-binding sequence is required for striatal distribution of the dopamine transporter. *Nat Commun* 4:1580. [CrossRef Medline](#)
- Rogaeva E et al. (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nat Genet* 39:168–177. [CrossRef Medline](#)
- Rojas R, van Vlijmen T, Mardones GA, Prabhu Y, Rojas AL, Mohammed S, Heck AJ, Raposo G, van der Sluijs P, Bonifacino JS (2008) Regulation of retromer recruitment to endosomes by sequential action of Rab5 and Rab7. *J Cell Biol* 183:513–526. [CrossRef Medline](#)
- Sakrikar D, Mazei-Robison MS, Mergy MA, Richtand NW, Han Q, Hamilton PJ, Bowton E, Galli A, Veenstra-Vanderweele J, Gill M, Blakely RD (2012) Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation. *J Neurosci* 32:5385–5397. [CrossRef Medline](#)
- Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. *Proc Natl Acad Sci U S A* 97:6850–6855. [CrossRef Medline](#)
- Sawa A, Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. *Science* 296:692–695. [CrossRef Medline](#)
- Schmid JA, Scholze P, Kudlacek O, Freissmuth M, Singer EA, Sitte HH (2001) Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. *J Biol Chem* 276:3805–3810. [CrossRef Medline](#)
- Seaman MN (2004) Cargo-selective endosomal sorting for retrieval to the Golgi requires retromer. *J Cell Biol* 165:111–122. [CrossRef Medline](#)
- Seaman MN (2012) The retromer complex: endosomal protein recycling and beyond. *J Cell Sci* 125:4693–4702. [CrossRef Medline](#)
- Seaman MN, Marcussen EG, Cereghino JL, Emr SD (1997) Endosome to Golgi retrieval of the vacuolar protein sorting receptor, Vps10p, requires the function of the VPS29, VPS30, and VPS35 gene products. *J Cell Biol* 137:79–92. [CrossRef Medline](#)
- Seaman MN, McCaffery JM, Emr SD (1998) A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. *J Cell Biol* 142:665–681. [CrossRef Medline](#)
- Seaman MN, Harbour ME, Tattersall D, Read E, Bright N (2009) Membrane recruitment of the cargo-selective retromer subcomplex is catalysed by the small GTPase Rab7 and inhibited by the Rab-GAP TBC1D5. *J Cell Sci* 122:2371–2382. [CrossRef Medline](#)
- Sharma A, Couture J (2014) A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). *Ann Pharmacother* 48:209–225. [CrossRef Medline](#)
- Small SA, Petsko GA (2015) Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. *Nat Rev Neurosci* 16:126–132. [CrossRef Medline](#)
- Sorkina T, Miranda M, Dionne KR, Hoover BR, Zahniser NR, Sorkin A (2006) RNA interference screen reveals an essential role of Nedd4–2 in dopamine transporter ubiquitination and endocytosis. *J Neurosci* 26:8195–8205. [CrossRef Medline](#)
- Steinberg F, Gallon M, Winfield M, Thomas EC, Bell AJ, Heesom KJ, Tavaré JM, Cullen PJ (2013) A global analysis of SNX27-retromer assembly and cargo specificity reveals a function in glucose and metal ion transport. *Nat Cell Biol* 15:461–471. [CrossRef Medline](#)
- St Pierre CA, Leonard D, Corvera S, Kurt-Jones EA, Finberg RW (2011) Antibodies to cell surface proteins redirect intracellular trafficking pathways. *Exp Mol Pathol* 91:723–732. [CrossRef Medline](#)
- Sulzer D, Schmitz Y (2007) Parkinson's disease: return of an old prime suspect. *Neuron* 55:8–10. [CrossRef Medline](#)
- Torres GE, Amara SG (2007) Glutamate and monoamine transporters: new visions of form and function. *Curr Opin Neurobiol* 17:304–312. [CrossRef Medline](#)
- Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, Staudinger J, Caron MG (2001) Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. *Neuron* 30:121–134. [CrossRef Medline](#)
- Tsika E, Glauser L, Moser R, Fiser A, Daniel G, Sheerin UM, Lees A, Troncoso JC, Lewis PA, Bandopadhyay R, Schneider BL, Moore DJ (2014) Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. *Hum Mol Genet* 23:4621–4638. [CrossRef Medline](#)
- Uttamapinant C, White KA, Baruah H, Thompson S, Fernández-Suárez M, Puthenveetil S, Ting AY (2010) A fluorophore ligase for site-specific protein labeling inside living cells. *Proc Natl Acad Sci U S A* 107:10914–10919. [CrossRef Medline](#)



- Uttamapinant C, Tangpeerachaikul A, Grecian S, Clarke S, Singh U, Slade P, Gee KR, Ting AY (2012) Fast, cell-compatible click chemistry with copper-chelating azides for biomolecular labeling. *Angew Chem Int Ed Engl* 51:5852–5856. [CrossRef Medline](#)
- Uttamapinant C, Sanchez MI, Liu DS, Yao JZ, Ting AY (2013) Site-specific protein labeling using PRIME and chelation-assisted click chemistry. *Nat Protoc* 8:1620–1634. [CrossRef Medline](#)
- van Weering JR, Verkade P, Cullen PJ (2012) SNX-BAR-mediated endosome tubulation is co-ordinated with endosome maturation. *Traffic* 13:94–107. [CrossRef Medline](#)
- Varandas KC, Irannejad R, von Zastrow M (2016) Retromer endosome exit domains serve multiple trafficking destinations and regulate local G protein activation by GPCRs. *Curr Biol* 26:3129–3142. [CrossRef Medline](#)
- Vuorenää A, Jørgensen TN, Newman AH, Madsen KL, Scheinin M, Gether U (2016) Differential internalization rates and postendocytic sorting of the norepinephrine and dopamine transporters are controlled by structural elements in the N termini. *J Biol Chem* 291:5634–5651. [CrossRef Medline](#)
- Welz T, Wellbourne-Wood J, Kerkhoff E (2014) Orchestration of cell surface proteins by Rab11. *Trends Cell Biol* 24:407–415. [CrossRef Medline](#)
- Wu S, Bellve KD, Fogarty KE, Melikian HE (2015) Ack1 is a dopamine transporter endocytic brake that rescues a trafficking-dysregulated ADHD coding variant. *Proc Natl Acad Sci U S A* 112:15480–15485. [CrossRef Medline](#)
- Zhang D, Isack NR, Glodowski DR, Liu J, Chen CC, Xu XZ, Grant BD, Rongo C (2012) RAB-6.2 and the retromer regulate glutamate receptor recycling through a retrograde pathway. *J Cell Biol* 196:85–101. [CrossRef Medline](#)